

# Ecstasy

MDMA and other ring-substituted amphetamines

Linda R. Gowing<sup>1</sup>  
Susan M. Henry-Hedwards<sup>1</sup>  
Rodney J. Irvine<sup>2</sup>  
Robert L. Ali<sup>1,2</sup>

<sup>1</sup>Drug and Alcohol Services Council and

<sup>2</sup>Clinical and Experimental Pharmacology University of Adelaide, South Australia, Australia



**World Health Organization**

Mental Health and Substance Dependence Department

---

© 2001 World Health Organization

This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however be freely reviewed, abstracted, reproduced or translated, in part or in whole, but not for sale or for use in conjunction with commercial purposes. The views expressed in the document by named authors are solely the responsibility of those authors.

# Table of Contents

<b>Acknowledgements</b> . . . . .	<b>v</b>	2.2.5.6	Slovenia . . . . .	8
<b>Executive Summary</b> . . . . .	<b>vi</b>	2.2.5.7	Ukraine . . . . .	8
<b>1. Introduction</b> . . . . .	<b>1</b>	2.2.6	Western Europe . . . . .	8
1.1 Background . . . . .	1	2.2.6.1	Austria . . . . .	8
1.2 Scope of the report . . . . .	1	2.2.6.2	Belgium . . . . .	8
1.3 Chemistry . . . . .	1	2.2.6.3	Denmark . . . . .	8
1.4 History . . . . .	3	2.2.6.4	Finland . . . . .	8
1.5 Manufacture . . . . .	3	2.2.6.5	France . . . . .	8
<b>2. Epidemiology</b> . . . . .	<b>4</b>	2.2.6.6	Germany . . . . .	9
2.1 Global spread . . . . .	4	2.2.6.7	Ireland . . . . .	9
2.2 Population prevalence of use . . . . .	5	2.2.6.8	Italy . . . . .	9
2.2.1 Africa and Middle Eastern Countries . . . . .	5	2.2.6.9	Luxembourg . . . . .	9
2.2.1.1 South Africa . . . . .	5	2.2.6.10	Netherlands . . . . .	9
2.2.2 North America . . . . .	5	2.2.6.11	Norway . . . . .	9
2.2.2.1 Canada . . . . .	5	2.2.6.12	Portugal . . . . .	10
2.2.2.2 United States of America . . . . .	6	2.2.6.13	Spain . . . . .	10
2.2.3 Latin America . . . . .	6	2.2.6.14	Sweden . . . . .	10
2.2.4 East Asia and Western Pacific . . . . .	6	2.2.6.15	United Kingdom . . . . .	10
2.2.4.1 Australia . . . . .	6	2.3	Context of use . . . . .	10
2.2.4.2 China . . . . .	6	2.3.1	Characteristics of users . . . . .	11
2.2.4.3 Indonesia . . . . .	7	2.3.1.1	Age . . . . .	11
2.2.4.4 Japan . . . . .	7	2.3.1.2	Gender . . . . .	11
2.2.4.5 Philippines . . . . .	7	2.3.1.3	Social Background . . . . .	11
2.2.4.6 Singapore . . . . .	7	2.3.2	Social context of use . . . . .	11
2.2.4.7 Thailand . . . . .	7	2.4	Pattern of use . . . . .	12
2.2.4.8 Vietnam . . . . .	7	2.4.1	Quantity and frequency . . . . .	12
2.2.5 Central and Eastern Europe . . . . .	7	2.4.2	Route of administration . . . . .	12
2.2.5.1 Croatia . . . . .	7	2.4.3	Polydrug use . . . . .	13
2.2.5.2 Hungary . . . . .	7	2.4.4	Planned use . . . . .	13
2.2.5.3 Poland . . . . .	7	2.4.5	Dependence . . . . .	13
2.2.5.4 Russian Federation . . . . .	8	<b>3. Pharmacology</b> . . . . .	<b>14</b>	
2.2.5.5 Slovakia . . . . .	8	3.1	Mechanism of action . . . . .	14

## Table of Contents

3.2	Animal pharmacology	14	5.4.1.12	Effect of MDMA dose	30
3.3	Effect in humans	15	5.4.2	Liver damage not involving hyperthermia	32
3.3.1	Controlled administration of MDMA	15	5.4.2.1	Relative contribution of ecstasy to liver injury	32
3.3.2	Surveys of users	15	5.4.2.2	Mechanism	33
3.3.3	Summary of effects	17	5.4.3	Psychiatric sequelae	33
3.4	Pharmacokinetics and metabolism	17	<b>6.</b>	<b>Prevention</b>	<b>35</b>
3.4.1	Absorption of MDMA	17	6.1	Primary prevention	35
3.4.2	Metabolism and elimination of MDMA	18	6.1.1	School drug education	35
3.4.3	Drug interactions	18	6.1.2	Mass media campaigns	36
<b>4.</b>	<b>Neurotoxicity</b>	<b>20</b>	6.1.3	Comprehensive community based strategies	36
4.1	Brain imaging studies	20	6.1.4	Tailoring prevention to ecstasy use	37
4.2	Functional studies	21	6.2	Secondary prevention	37
4.3	Long-term effects of MDMA	23	6.3	Tertiary prevention	38
4.4	Mechanisms of MDMA-induced neurotoxicity	24	<b>7.</b>	<b>Treatment</b>	<b>39</b>
<b>5.</b>	<b>Health consequences</b>	<b>25</b>	7.1	Interventions directed at using behaviour	39
5.1	Review approach	25	7.2	Responses to conditions induced by ecstasy	40
5.2	Importance of setting	25	7.2.1	Adverse effects of intoxication	40
5.3	Prevalence of adverse effects	25	7.2.2	Hepatotoxicity	41
5.4	Cases of health effects attributed to ecstasy	26	<b>8.</b>	<b>Concluding remarks</b>	<b>43</b>
5.4.1	Acute adverse effects	26	8.1	Preventing harms	43
5.4.1.1	Hyperthermia	27	8.2	Future directions in research	43
5.4.1.2	Disturbed salt and water balance	28	<b>Appendix 1:</b>	<b>Acute reactions to ecstasy involving hyperthermia</b>	<b>45</b>
5.4.1.3	Central nervous system effects (seizures)	28	<b>Appendix 2:</b>	<b>Acute adverse effects not involving hyperthermia</b>	<b>53</b>
5.4.1.4	Cardiac factors	28	<b>Appendix 3:</b>	<b>Cases of liver damage not involving hyperthermia</b>	<b>62</b>
5.4.1.5	Probable haemorrhages or cerebrovascular accidents	29	<b>Appendix 4:</b>	<b>Psychiatric sequelae</b>	<b>67</b>
5.4.1.6	Respiratory factors	29	<b>Glossary of terms and abbreviations</b>	<b>72</b>	
5.4.1.7	Trauma whilst intoxicated	29	<b>References</b>	<b>74</b>	
5.4.1.8	Chest pain not related to cardiac factors	29			
5.4.1.9	Ophthalmic conditions	29			
5.4.1.10	Aplastic anaemia	30			
5.4.1.11	Miscellaneous cases	30			

---

# Acknowledgements

WHO gratefully acknowledges the assistance of the following collaborators who contributed in various ways to the preparation, review or finalization of this document:

**Dr Ian Seppelt**  
St George Hospital  
Sydney, Australia

**Dr Linda Chang**  
Scientist and Chair  
Medical Department  
Brookhaven National Laboratory, Upton, New York, USA

**Ms Jennifer Hillebrand**  
technical officer  
WHO Management of Substance Dependence

**Ms Raquel Shaw Moxam**  
technical officer  
WHO Management of Substance Dependence

**Dr Maristela Monteiro**  
Coordinator  
WHO Management of Substance Dependence

This work was funded by the United Nations Office for Drug Control and Crime Prevention (ODCCP) and by the Ministry of Health and Welfare of Japan.

---

# Executive Summary

## Executive Summary

The term "ecstasy" is primarily applied to 3,4-methylenedioxymethamphetamine (MDMA) but other drugs are sold as ecstasy, and ecstasy tablets can contain a range of drugs in addition to, or in place of, MDMA.

MDMA combines stimulant and hallucinogenic properties. Its use has been associated with a global trend of dance parties and "techno" or dance music.

In the 1970s, MDMA was increasingly being used in the USA as an adjunct to psychotherapy. In 1985, the US Food and Drug Administration classified MDMA as Schedule I (no acceptable therapeutic use). Debate regarding the decision may have unintentionally increased public awareness of the drug and its psychoactive effects.

Illicit production of MDMA is relatively easy but quality control is difficult to achieve. Forensic analysis of drugs seized as "ecstasy" have revealed other amphetamine-type stimulants as well as chemically unrelated compounds with little or no psychotropic activity. Wide variations in the dose of MDMA contained in tablets have also been detected.

Epidemiological information on ecstasy use is sparse and data collection procedures are variable, complicating analysis. However, it is clear that there was significant growth in the popularity of amphetamine-type stimulants during the 1990s with use now a global phenomenon.

Data from Europe and the USA indicate that ecstasy has ever been tried by between 0.5 and three per cent of the general population and from one to five per cent of young adults. In general ecstasy is the third most used illicit drug, after cannabis and amphetamines.

In most countries ecstasy is used recreationally as part of a particular youth culture centred on dance parties and raves and a preference for specific types of music. Users tend to be young, well educated, socially well integrated, with high levels of employment and less likely to have a criminal record than other populations of illicit drug users. However, ecstasy is also part of a pattern of polydrug use.

Sociability is a major characteristic of ecstasy use. It is almost exclusively taken in a social setting with part-

ners or groups of friends. Users particularly seek the feelings of empathy and closeness with others, which result from ecstasy use, to foster a group identity and sense of belonging. Use of ecstasy by friends is a significant factor in initiation and continuation of ecstasy use.

Ecstasy is associated with a variety of specific cultural trends in particular networks where the importance of the group is emphasised, for example the gay club and party scene and the "techno" music scene.

Ecstasy is primarily used recreationally, mainly at weekends in association with social events, but studies, particularly in the UK and Australia, have identified regular and intensive use. There may also be a trend of increasing use by injection. Most users appear able to regulate their use of ecstasy but some progress to problematic use. Some researchers have suggested that problematic use might constitute dependence but this is an aspect for further debate.

MDMA has high affinity for serotonin receptors and transport sites in the brain. Serotonin-producing neurones in the brain regulate aggression, mood, sexual activity, sleep and sensitivity to pain. Serotonin is also important in memory and temperature regulation.

MDMA initially enhances extracellular brain concentrations of serotonin, but eventually this leads to depletion of the neurotransmitter and hence a decrease in serotonin levels. MDMA also increases release of dopamine, another neurotransmitter that is involved in the control of movement, cognition, motivation and reward.

Findings of surveys of users and studies using controlled administration of MDMA are consistent, namely immediate positive psychological effects of euphoria, increased energy, and a feeling of closeness to others, and negative psychological effects of paranoia, anxiety and depression. Common short-term physical effects are pupil dilation, increased jaw tension and grinding of teeth, loss of appetite, dry mouth, tachycardia, hot and cold flushes, and sweaty palms. Longer term effects reported by users include insomnia, depression, headaches and muscle stiffness.

Tolerance to the effects of MDMA appears to develop rapidly. In surveys users report a decrease in "positive" effects and an increase in "negative" effects

with successive doses. "Negative" effects are also reported to increase, and "positive" effects decrease, with increasing doses of ecstasy.

MDMA is well absorbed from the gastrointestinal tract. Following oral administration, effects become apparent in about 20 minutes and last for about four hours. Recent evidence indicates that the relationship between MDMA dose and blood concentration may not be linear. Hence small increases in dose may produce disproportionate increases in effect, possibly contributing to toxicity.

In the liver, MDMA is metabolised by a number of cytochrome P450-mediated pathways. One of the enzymes involved, CYP2D6 exhibits genetic variability such that some people have low activity of the enzyme and are denoted poor metabolisers. It has been suggested that these people, due to reduced metabolism, will be at greater risk of MDMA toxicity. However, no evidence has been found to support this hypothesis. It is likely that, *in vivo*, other enzyme pathways make up for the deficit. Some of the metabolic products of MDMA are bioactive and may also contribute to toxicity. MDMA is metabolised in the liver and eliminated via the urine.

Drug interactions may influence MDMA toxicity by altering the elimination of MDMA from the body, or through an additive effect if the interacting drug has a similar effect to MDMA. Reported cases of adverse reactions possibly arising from drug interaction involved fluoxetine (two cases) and ritonavir (one case).

Animal studies have shown that administration of MDMA produces damage to axons and axon terminal fibres containing serotonin. Decreases in the density of brain serotonin axons have been seen in squirrel monkeys more than seven years after MDMA administration. Some regrowth of axons occurs, but is abnormal and incomplete.

These findings in animals are the basis of concerns regarding neurotoxicity of MDMA. Although animal studies are indicative of effects in humans, there always remains a degree of uncertainty about transferability of findings. However, a series of studies using sophisticated brain imaging techniques to assess different aspects of the human brain have found persisting abnormalities in brain morphology in ex-users of ecstasy, even with moderate use. These studies tended to use small numbers of users and many are confounded by uncertain histories of MDMA use and use of other drugs. Although providing additional evidence of neurotoxicity, these imag-

ing studies do not indicate the functional significance of the changes in brain morphology.

The functional significance of the neurotoxic effects of ecstasy has been explored in a number of recent studies using psychological tests to assess cognitive function, memory and aspects of mood in current and former ecstasy users compared to non-using controls. Again, these studies are confounded to some extent by small numbers of participants, difficulties in determining histories of ecstasy use, concomitant use of other drugs such as cannabis, and the lack of baseline data from periods prior to ecstasy use (some differences between ecstasy users and non-users, such as impulsivity, may reflect existing personality differences rather than the effects of ecstasy). Despite these limitations, and despite some variability between studies, there is a consistent finding of impairment in short-term memory function in ecstasy users that cannot be attributed to concomitant use of other drugs, in particular cannabis.

Overall the combination of animal and human studies constitutes mounting evidence of ecstasy having a neurotoxic effect. However, the long-term functional consequences of ecstasy use in humans will remain uncertain pending large scale epidemiological studies. The mechanism of MDMA's neurotoxicity is also uncertain, and an area of active research.

Any analysis of case reports of adverse health effects will inevitably be biased. More serious effects, particularly cases with fatal outcomes, and more unusual cases are more likely to be published. Published reports are also likely to follow areas of debate at a particular time, such as the use of dantrolene in the treatment of ecstasy-related hyperthermia. A further limitation of case report analysis is the inability to relate the number of case reports to a population base. This makes it impossible to quantify relative risks of the various adverse effects reported. However, in the absence of structured epidemiological studies, analysis of case reports constitutes the best evidence available on the risks associated with use of ecstasy.

The first reports of deaths involving MDMA use appeared in scientific literature around 1987. A subsequent surge in case reports of significant health effects seems to be associated with a change in the setting in which the drug was most commonly used – from the clinical psychotherapy setting of the 1970s to the dance party and "rave" setting of the 1990s. MDMA can produce hyperthermia in quiet surroundings, when taken in sufficient quantity, but in the setting of "raves" or dance parties, the toxicity

## Executive Summary

appears to be enhanced. It is probably a combination of direct effects of MDMA, high ambient temperature, sustained physical activity and inadequate fluid replacement, all impairing temperature regulation, that creates the greatest toxicity.

Given the hundreds of thousands of ecstasy tablets that are probably consumed each weekend, the number of published cases of adverse effects (we located 160) is very small. This, combined with the findings of the surveys of users that have been undertaken, indicates that the prevalence of serious acute adverse events arising from ecstasy use is low. It is the unpredictability of those adverse events and the risk of mortality and substantial morbidity in young people that makes the health consequences of ecstasy significant.

We identified from published reports, 69 separate cases of acute reactions to "ecstasy" involving hyperthermia, 48% of which resulted in death.

Hyperthermia is typically accompanied by a number of clinical problems, induced or made worse by the hyperthermia, including seizures or convulsions, abnormalities in blood coagulation, rhabdomyolysis, and impairment of kidney and liver function. There is an apparent correlation between body temperature and mortality, with around two-thirds of cases where the body temperature exceeded 41.5°C ending in death.

This data emphasises rapid reduction of temperature as the most important response to hyperthermia related to MDMA use. It also indicates the importance of educating users on strategies to avoid hyperthermia, and to seek medical assistance promptly if hyperthermia becomes apparent.

Adequate fluid intake and rest periods in a cool room are important measures for the prevention of hyper

- cerebral ischaemia or blood vessel ruptures (possibly related to the stimulatory action of ecstasy, or to the presence of amphetamine in the "ecstasy" or taken concurrently with "ecstasy");
- respiratory difficulties;
- trauma whilst intoxicated;
- chest pain not related to cardiac factors (air in tissues, spasm of intercostal muscles from strenuous exercise);
- ophthalmic conditions (probably related to extended periods of activity with reduced blinking and tear formation); and
- aplastic anaemia (the link with ecstasy use is unclear).

Longer term physical effects include excessive tooth-wear arising from tooth-grinding and jaw clenching associated with ecstasy use. One limited study has also identified a possible increased risk of birth defects following ecstasy use during pregnancy. The study had insufficient statistical power to confirm a causal relation but, given the young age of ecstasy users, is an aspect that should be monitored.

An issue with analysis of case reports is the lack of certainty as to the nature and amount of drugs consumed, which makes it difficult to attribute adverse effects specifically to MDMA use. For 108 of the 158 cases of acute adverse effects we examined, drug use was confirmed by analysis of blood and/or urine samples. Although these analyses indicate the presence, in some cases, of a number of amphetamine derivatives, alcohol or other drugs, they also support a conclusion that MDMA alone can produce adverse effects including hyperthermia, disturbances of sodium and fluid balance, disturbances of cardiac func-

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_30444](https://www.yunbaogao.cn/report/index/report?reportId=5_30444)

